These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 9131143)
1. Systemic administration of alkylphosphocholines. Erucylphosphocholine and liposomal hexadecylphosphocholine. Kaufmann-Kolle P; Berger MR; Unger C; Eibl H Adv Exp Med Biol; 1996; 416():165-8. PubMed ID: 9131143 [No Abstract] [Full Text] [Related]
2. Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine. Kaufmann-Kolle P; Drevs J; Berger MR; Kötting J; Marschner N; Unger C; Eibl H Cancer Chemother Pharmacol; 1994; 34(5):393-8. PubMed ID: 8070005 [TBL] [Abstract][Full Text] [Related]
3. Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations. Kötting J; Berger MR; Unger C; Eibl H Cancer Chemother Pharmacol; 1992; 30(2):105-12. PubMed ID: 1600590 [TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of alkylphosphocholines and analogues in methylnitrosourea-induced rat mammary carcinomas. Berger MR; Yanapirut P; Reinhardt M; Klenner T; Scherf HR; Schmeiser HH; Eibl H Prog Exp Tumor Res; 1992; 34():98-115. PubMed ID: 1438807 [No Abstract] [Full Text] [Related]
5. Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. Erdlenbruch B; Jendrossek V; Gerriets A; Vetterlein F; Eibl H; Lakomek M Cancer Chemother Pharmacol; 1999; 44(6):484-90. PubMed ID: 10550569 [TBL] [Abstract][Full Text] [Related]
6. Antineoplastic activity in vitro of free and liposomal alkylphosphocholines. Zeisig R; Jungmann S; Arndt D; Schütt A; Nissen E Anticancer Drugs; 1993 Feb; 4(1):57-64. PubMed ID: 8457716 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the tissue distribution of hexadecylphosphocholine and erucylphosphocholine. Reitz RC; Kötting J; Unger C; Eibl H Prog Exp Tumor Res; 1992; 34():143-52. PubMed ID: 1438797 [No Abstract] [Full Text] [Related]
8. Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice. Arndt D; Zeisig R; Fichtner I; Teppke AD; Fahr A Breast Cancer Res Treat; 1999 Nov; 58(1):71-80. PubMed ID: 10634520 [TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of alkylphosphocholines in different murine tumor models: use of liposomal preparations. Zeisig R; Fichtner I; Arndt D; Jungmann S Anticancer Drugs; 1991 Aug; 2(4):411-7. PubMed ID: 1797199 [TBL] [Abstract][Full Text] [Related]
10. In vitro investigations on the antineoplastic effect of hexadecylphosphocholine. Yanapirut P; Berger MR; Reinhardt M; Schmähl D Arzneimittelforschung; 1991 Jun; 41(6):652-5. PubMed ID: 1930356 [TBL] [Abstract][Full Text] [Related]
11. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma. Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343 [TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo antitumoral activity of alkylphosphonates. Ries UJ; Fleer EA; Breiser A; Unger C; Stekar J; Fenneberg K; Eibl H Eur J Cancer; 1992; 29A(1):96-101. PubMed ID: 1445752 [TBL] [Abstract][Full Text] [Related]
13. Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133. Stekar J; Hilgard P; Voegeli R; Maurer HR; Engel J; Kutscher B; Nössner G; Schumacher W Cancer Chemother Pharmacol; 1993; 32(6):437-44. PubMed ID: 8258191 [TBL] [Abstract][Full Text] [Related]
14. Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution. Kötting J; Marschner NW; Neumüller W; Unger C; Eibl H Prog Exp Tumor Res; 1992; 34():131-42. PubMed ID: 1438796 [No Abstract] [Full Text] [Related]
15. Hexadecylphosphocholine differs from conventional cytostatic agents. Berger MR; Betsch B; Gebelein M; Amtmann E; Heyl P; Scherf HR J Cancer Res Clin Oncol; 1993; 119(9):541-8. PubMed ID: 8392075 [TBL] [Abstract][Full Text] [Related]
16. Erucylphosphocholine, a novel antineoplastic ether lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro. Jendrossek V; Erdlenbruch B; Hunold A; Kugler W; Eibl H; Lakomek M Int J Oncol; 1999 Jan; 14(1):15-22. PubMed ID: 9863004 [TBL] [Abstract][Full Text] [Related]
17. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Hilgard P; Klenner T; Stekar J; Nössner G; Kutscher B; Engel J Eur J Cancer; 1997 Mar; 33(3):442-6. PubMed ID: 9155530 [TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo. Erdlenbruch B; Jendrossek V; Marx M; Hunold A; Eibl H; Lakomek M Anticancer Res; 1998; 18(4A):2551-7. PubMed ID: 9703909 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of release and pharmacokinetics of hexadecylphosphocholine (miltefosine) in phosphatidyldiglycerol-based thermosensitive liposomes. Rysin A; Paal M; Lokerse WJM; Wedmann B; Hossann M; Vogeser M; Winter G; Lindner LH Biochim Biophys Acta Biomembr; 2021 Nov; 1863(11):183698. PubMed ID: 34283999 [TBL] [Abstract][Full Text] [Related]
20. Hexadecylphosphocholine: a new and selective antitumor drug. Eibl H; Unger C Cancer Treat Rev; 1990 Sep; 17(2-3):233-42. PubMed ID: 2272038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]